Synergistic Effects of Lactobacillus acidophilus and Balanites aegyptiaca in Managing Hyperglycemia, Oxidative Stress, and Inflammation in Diabetic Rats.
Dalia Elebeedy, Nada Elgendy, Aml Ghanem, Aya Salem, Muhammad Alaa Eldeen, Mohamed A Ali, Dalal Sulaiman Alshaya, Maha A Aljumaa, Hanadi A Katouah, Eman Fayad, Ghadi Alsharif, Ahmed I Abd El Maksoud
{"title":"Synergistic Effects of Lactobacillus acidophilus and Balanites aegyptiaca in Managing Hyperglycemia, Oxidative Stress, and Inflammation in Diabetic Rats.","authors":"Dalia Elebeedy, Nada Elgendy, Aml Ghanem, Aya Salem, Muhammad Alaa Eldeen, Mohamed A Ali, Dalal Sulaiman Alshaya, Maha A Aljumaa, Hanadi A Katouah, Eman Fayad, Ghadi Alsharif, Ahmed I Abd El Maksoud","doi":"10.2174/0113892010362400250121075011","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Diabetes mellitus is a chronic condition characterized by persistent hyperglycemia, which can lead to serious complications if not managed effectively. Recent interest has grown in exploring the potential of probiotics and prebiotics as complementary therapies. This study investigates the combined effects of the probiotic Lactobacillus acidophilus and the prebiotic Balanites aegyptiaca on blood glucose levels, oxidative stress, and inflammatory markers in an alloxan-induced diabetic rat model.</p><p><strong>Methods: </strong>A total of 40 male rats (100-110 g; 8-10 weeks) were randomly divided into five groups: a normal control group, a diabetic control group, and diabetic groups treated with Lactobacillus acidophilus, Balanites aegyptiaca, or their combination. The mice in the diabetic groups were orally treated with 28.5 mg/kg of Lactobacillus acidophilus, Balanites aegyptiaca, or both twice daily for 30 days. Blood glucose levels were measured before and after treatment. Antioxidant enzyme activities, including glutathione peroxidase, glutathione reductase, glutathione Stransferase, catalase, and superoxide dismutase, were assessed. Inflammatory cytokines (TNF-α and IL-6) and lipid profiles (cholesterol and triglycerides) were also evaluated.</p><p><strong>Results: </strong>The combination of Lactobacillus acidophilus and Balanites aegyptiaca significantly reduced blood glucose levels in diabetic rats from 295 mg/dl to 114 mg/dl, outperforming the effects of either treatment alone. Antioxidant enzyme activities were markedly enhanced in the combined treatment group, indicating reduced oxidative stress. The combined therapy also significantly decreased pro-inflammatory cytokines TNF-α and IL-6 compared to the diabetic control group. Furthermore, lipid profiles showed improved cholesterol and triglyceride levels in the combined treatment group, even in a high-lipid diet.</p><p><strong>Conclusion: </strong>The combination of Lactobacillus acidophilus and Balanites aegyptiaca reduced hyperglycemia, oxidative stress, and inflammation in diabetic rats, suggesting potential as a complementary diabetes therapy.</p>","PeriodicalId":10881,"journal":{"name":"Current pharmaceutical biotechnology","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical biotechnology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113892010362400250121075011","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Diabetes mellitus is a chronic condition characterized by persistent hyperglycemia, which can lead to serious complications if not managed effectively. Recent interest has grown in exploring the potential of probiotics and prebiotics as complementary therapies. This study investigates the combined effects of the probiotic Lactobacillus acidophilus and the prebiotic Balanites aegyptiaca on blood glucose levels, oxidative stress, and inflammatory markers in an alloxan-induced diabetic rat model.
Methods: A total of 40 male rats (100-110 g; 8-10 weeks) were randomly divided into five groups: a normal control group, a diabetic control group, and diabetic groups treated with Lactobacillus acidophilus, Balanites aegyptiaca, or their combination. The mice in the diabetic groups were orally treated with 28.5 mg/kg of Lactobacillus acidophilus, Balanites aegyptiaca, or both twice daily for 30 days. Blood glucose levels were measured before and after treatment. Antioxidant enzyme activities, including glutathione peroxidase, glutathione reductase, glutathione Stransferase, catalase, and superoxide dismutase, were assessed. Inflammatory cytokines (TNF-α and IL-6) and lipid profiles (cholesterol and triglycerides) were also evaluated.
Results: The combination of Lactobacillus acidophilus and Balanites aegyptiaca significantly reduced blood glucose levels in diabetic rats from 295 mg/dl to 114 mg/dl, outperforming the effects of either treatment alone. Antioxidant enzyme activities were markedly enhanced in the combined treatment group, indicating reduced oxidative stress. The combined therapy also significantly decreased pro-inflammatory cytokines TNF-α and IL-6 compared to the diabetic control group. Furthermore, lipid profiles showed improved cholesterol and triglyceride levels in the combined treatment group, even in a high-lipid diet.
Conclusion: The combination of Lactobacillus acidophilus and Balanites aegyptiaca reduced hyperglycemia, oxidative stress, and inflammation in diabetic rats, suggesting potential as a complementary diabetes therapy.
期刊介绍：
Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal includes timely in-depth reviews, original research articles and letters written by leaders in the field, covering a range of current topics in scientific areas of Pharmaceutical Biotechnology. Invited and unsolicited review articles are welcome. The journal encourages contributions describing research at the interface of drug discovery and pharmacological applications, involving in vitro investigations and pre-clinical or clinical studies. Scientific areas within the scope of the journal include pharmaceutical chemistry, biochemistry and genetics, molecular and cellular biology, and polymer and materials sciences as they relate to pharmaceutical science and biotechnology. In addition, the journal also considers comprehensive studies and research advances pertaining food chemistry with pharmaceutical implication. Areas of interest include:
DNA/protein engineering and processing
Synthetic biotechnology
Omics (genomics, proteomics, metabolomics and systems biology)
Therapeutic biotechnology (gene therapy, peptide inhibitors, enzymes)
Drug delivery and targeting
Nanobiotechnology
Molecular pharmaceutics and molecular pharmacology
Analytical biotechnology (biosensing, advanced technology for detection of bioanalytes)
Pharmacokinetics and pharmacodynamics
Applied Microbiology
Bioinformatics (computational biopharmaceutics and modeling)
Environmental biotechnology
Regenerative medicine (stem cells, tissue engineering and biomaterials)
Translational immunology (cell therapies, antibody engineering, xenotransplantation)
Industrial bioprocesses for drug production and development
Biosafety
Biotech ethics
Special Issues devoted to crucial topics, providing the latest comprehensive information on cutting-edge areas of research and technological advances, are welcome.
Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
